Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3460970 | 0.84 | CYP3A4 (0.35) | CYP3A4GABRA1GABRB2 | |
| SCHEMBL10952512 | 0.74 | CYP3A4 (0.32) | CYP3A4GABRA1GABRB2 | |
| SCHEMBL4774935 | 0.74 | CYP3A4 (0.36) | CYP3A4GABRA1GABRB2 | |
| SCHEMBL1587172 | 0.74 | GABRA1 (0.34) | CYP3A4GABRA1GABRB2 | |
| SCHEMBL1996910 | 0.74 | CYP3A4 (0.36) | CYP3A4GABRA1GABRB2 | |
| SCHEMBL699436 | 0.74 | GABRA1 (0.34) | CYP3A4GABRA1GABRB2 | |
| SCHEMBL2835593 | 0.73 | CYP3A4 (0.46) | CYP3A4GABRA1GABRB2 | |
| SCHEMBL57779 | 0.73 | CYP3A4 (0.46) | CYP3A4GABRA1GABRB2 | |
| SCHEMBL1989667 | 0.73 | GABRA1 (0.37) | GABRA1GABRB2 | |
| SCHEMBL7747680 | 0.71 | CYP3A4 (0.44) | CYP3A4GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678168-B1 | P70S6 KINASE MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7816353-B2 | P70S6 kinase modulators and method of use | EXELIXIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EXELIXIS, INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EEF2K, RPS6KA3, MTOR | CYP3A4 4833/4885GABRA1 3754/4885GABRB2 2298/4885 |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EEF2K, RPS6KA3, MTOR | CYP3A4 4833/4885GABRA1 3754/4885GABRB2 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.